2-[6-(2,3-dihydro-1H-inden-2-ylamino)-1-ethyl-4-oxo-1,8-naphthyridin-3-yl]-2-oxoacetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[6-(2,3-dihydro-1H-inden-2-ylamino)-1-ethyl-4-oxo-1,8-naphthyridin-3-yl]-2-oxoacetic acid
• 化学式: C₂₁H₁₉N₃O₄
• 分子量: 377.4
• InChiKey: NBQJSINJXVYLFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• A CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND
  申请人：Bionomics Limited

  公开号：EP2970290B1

  公开（公告）日：2020-07-22
• CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND
  申请人：Bionomics Limited

  公开号：US20170305905A1

  公开（公告）日：2017-10-26

  The present invention provides a crystalline Form B of compound 1, and pharmaceutically compositions thereof. The present invention also provides methods of treating a disease (e.g., a disease of the central nervous system) using the pharmaceutical compositions.
• US9758516B2
  申请人：——

  公开号：US9758516B2

  公开（公告）日：2017-09-12
• [EN] A CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND<br/>[FR] FORME CRISTALLINE D'UN COMPOSÉ ANXIOLYTIQUE
  申请人：BIONOMICS LTD

  公开号：WO2014138772A1

  公开（公告）日：2014-09-18

  The present invention provides a crystalline Form B of compound 1, and pharmaceutically compositions thereof. The present invention also provides methods of treating a disease (e.g., a disease of the central nervous system) using the pharmaceutical compositions.